Pages that link to "Q40377835"
Jump to navigation
Jump to search
The following pages link to Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. (Q40377835):
Displaying 50 items.
- Akt and mTOR in B Cell Activation and Differentiation (Q21131224) (← links)
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma (Q24607479) (← links)
- Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling (Q24673299) (← links)
- Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma (Q27026544) (← links)
- Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells (Q28544009) (← links)
- A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas (Q33409982) (← links)
- A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice (Q33449060) (← links)
- Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells (Q33941240) (← links)
- Rapalogs in viral cancers (Q34160579) (← links)
- Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. (Q34260622) (← links)
- Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma (Q34448586) (← links)
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma (Q34617756) (← links)
- The mTOR signaling pathway as a treatment target for intracranial neoplasms (Q34886859) (← links)
- Role of mTOR downstream effector signaling molecules in Francisella tularensis internalization by murine macrophages. (Q35061591) (← links)
- Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes. (Q35088231) (← links)
- Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS (Q35220408) (← links)
- Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma (Q35235757) (← links)
- The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside (Q35582498) (← links)
- Oncogenic viruses and tumor glucose metabolism: like kids in a candy store (Q35671327) (← links)
- Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma (Q35696506) (← links)
- Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma (Q35832407) (← links)
- Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma (Q35848973) (← links)
- Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. (Q36301590) (← links)
- IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. (Q36445869) (← links)
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells (Q36835733) (← links)
- (13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism (Q37004918) (← links)
- Possible mechanisms of disease development in tuberous sclerosis (Q37051667) (← links)
- Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas (Q37074284) (← links)
- Temsirolimus for the treatment of mantle cell lymphoma (Q37810084) (← links)
- Signal transduction inhibitor therapy for lymphoma (Q37829224) (← links)
- Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma (Q39328727) (← links)
- STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression (Q40070793) (← links)
- Brain tumor formation in tuberous sclerosis depends on Erk activation (Q40107921) (← links)
- Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma (Q40144368) (← links)
- Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. (Q40160132) (← links)
- Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. (Q40213973) (← links)
- The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas (Q41909242) (← links)
- Effects of PI3K catalytic subunit and Akt isoform deficiency on mTOR and p70S6K activation in myoblasts (Q42460800) (← links)
- Activation of mTORC1 signaling pathway in AIDS-related lymphomas (Q42592331) (← links)
- Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway (Q43250891) (← links)
- mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. (Q44536883) (← links)
- Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli. (Q45981746) (← links)
- Measuring phosphorylated Akt and other phosphoinositide 3-kinase-regulated phosphoproteins in primary lymphocytes. (Q46015581) (← links)
- The PI3K Pathway in Human Disease (Q46546002) (← links)
- Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities. (Q46908759) (← links)
- Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. (Q53605317) (← links)
- Challenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases (Q59136496) (← links)
- Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies (Q60046968) (← links)
- Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies (Q84556627) (← links)
- Glycolytic reprogramming of macrophages activated by NOD1 and TLR4 agonists: No association with proinflammatory cytokine production in normoxia (Q89473508) (← links)